CLINICAL TRIALS PROFILE FOR DWP14012

Clinical Trials for DWP14012

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02757144 ↗	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers	Completed	Daewoong Pharmaceutical Co. LTD.	Phase 1	This is a dose block-randomized, double-blind, placebo- and active-controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of DWP14012 after oral administration in healthy male volunteers.
NCT03184324 ↗	Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)	Completed	Daewoong Pharmaceutical Co. LTD.	Phase 2	The purpose of this study is to determine the efficacy and safety of DWP14012 compared to esomeprazole in the treatment of erosive gastroesophageal reflux disease classified as Los Angeles(LA) classification grades A to D.
NCT03487562 ↗	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects	Completed	Daewoong Pharmaceutical Co. LTD.	Phase 1	This is a randomized, open-label, multiple dose, two-part phase I clinical trial to compare the pharmacokinetics, pharmacodynamics and safety/tolerability of DWP14012 after administrations of DWP14012 alone and combinations of DWP14012, Clarithromycin and Amoxicillin in healthy male subjects
NCT03574415 ↗	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Japanese, Caucasian and Korean	Completed	Daewoong Pharmaceutical Co. LTD.	Phase 1	To evaluate the safety and tolerability of single and multiple ascending oral doses of DWP14012 in healthy Japanese, Caucasian and Korean subjects
NCT03736369 ↗	Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)	Completed	Daewoong Pharmaceutical Co. LTD.	Phase 3	The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.
NCT03811080 ↗	Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease	Unknown status	Daewoong Pharmaceutical Co. LTD.	Phase 3	The purpose of this study is to demonstrate the superiority of efficacy of DWP14012, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4.
NCT03811080 ↗	Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease	Unknown status	Sun Young, Kim	Phase 3	The purpose of this study is to demonstrate the superiority of efficacy of DWP14012, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4.

Clinical Trial Conditions for DWP14012

Condition Name

Condition Name
Intervention	Trials
Healthy	6
Drug Drug Interaction	3
Erosive Esophagitis	3
Phase 1 Study, Healthy Volunteers	2

Condition MeSH

Condition MeSH
Intervention	Trials
Esophagitis	5
Gastroesophageal Reflux	5
Esophagitis, Peptic	3
Peptic Ulcer	1

Clinical Trial Locations for DWP14012

Trials by Country

Trials by Country
Location	Trials
Korea, Republic of	20
China	2
Australia	1

Clinical Trial Progress for DWP14012

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	7
Phase 2	1
Phase 1	14

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	8
Recruiting	7
Unknown status	3

Clinical Trial Sponsors for DWP14012

Sponsor Name

Sponsor Name
Sponsor	Trials
Daewoong Pharmaceutical Co. LTD.	24
Sun Young, Kim	1
Hanyang University	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	26
Other	2